Climb Bio, Inc.
CLYMFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Climb Bio, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 30, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2026-03-31 | 1,334,130 | $9.14M | SEC filing |
| MPM BIOIMPACT LLC | 2026-03-31 | 2,593,439 | $17.8M | SEC filing |
| JONES FINANCIAL COMPANIES LLLP | 2026-03-31 | 266 | $1.87K | SEC filing |
| RENAISSANCE TECHNOLOGIES LLC | 2026-03-31 | 217,300 | $1.49M | SEC filing |
| ArchPoint Investors | 2026-03-31 | 121,400 | $832K | SEC filing |
| Kynam Capital Management, LP | 2026-03-31 | 1,003,341 | $6.87M | SEC filing |
| NORTHERN TRUST CORP | 2026-03-31 | 127,904 | $876K | SEC filing |
| Balyasny Asset Management L.P. | 2026-03-31 | 6,959 | $47.7K | SEC filing |
| DIADEMA PARTNERS LP | 2026-03-31 | 286,126 | $1.96M | SEC filing |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 2026-03-31 | 156,317 | $1.07M | SEC filing |
| ADAR1 Capital Management, LLC | 2026-03-31 | 597,662 | $4.09M | SEC filing |
| STATE STREET CORP | 2026-03-31 | 132,000 | $904K | SEC filing |
| NAN FUNG TRINITY (HK) LTD | 2026-03-31 | 420,517 | $2.88M | SEC filing |
| Qube Research & Technologies Ltd | 2026-03-31 | 104,217 | $714K | SEC filing |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 2026-03-31 | 134,300 | $920K | SEC filing |
| Advisory Services Network, LLC | 2026-03-31 | 2,032 | $13.9K | SEC filing |
| MILLENNIUM MANAGEMENT LLC | 2026-03-31 | 1,276,260 | $8.74M | SEC filing |
| HRT FINANCIAL LP | 2026-03-31 | 37,161 | Not shown | SEC filing |
| Squarepoint Ops LLC | 2026-03-31 | 42,974 | $294K | SEC filing |
| RAYMOND JAMES FINANCIAL INC | 2026-03-31 | 17,727 | $121K | SEC filing |
- Each value is checked against Climb Bio, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Climb Bio, Inc.'s share price.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- CWM, LLC: 29 shares reported 2025-12-31; 18 shares reported 2026-03-31.
- RA CAPITAL MANAGEMENT, L.P.: 11,293,828 shares reported 2025-12-31; 11,300,939 shares reported 2026-03-31.
- MORGAN STANLEY: 148,538 shares reported 2025-12-31; 234,182 shares reported 2026-03-31.
- BNP PARIBAS FINANCIAL MARKETS: 513 shares reported 2025-12-31; 29,128 shares reported 2026-03-31.
- Peapod Lane Capital LLC: 565,992 shares reported 2025-12-31; 108,878 shares reported 2026-03-31.
- Tower Research Capital LLC (TRC): 3,357 shares reported 2025-12-31; 5,836 shares reported 2026-03-31.
- NISA INVESTMENT ADVISORS, LLC: 573 shares reported 2025-12-31; 573 shares reported 2026-03-31.
- UBS Group AG: 71,323 shares reported 2025-12-31; 85,945 shares reported 2026-03-31.
- BLAIR WILLIAM & CO/IL: 11,000 shares reported 2025-12-31; 12,000 shares reported 2026-03-31.
- JPMORGAN CHASE & CO: 46 shares reported 2025-12-31; 46 shares reported 2026-03-31.
- DEUTSCHE BANK AG\: 1 share reported 2025-12-31; 1 share reported 2026-03-31.
- TD Asset Management Inc: 246,200 shares reported 2025-12-31; 250,102 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
52 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Climb Bio, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-12 · Thomas Stephen Basil: Larger than all 25 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-29 | Brennan Aoife · President and CEO | Common Stock | S — Open market or private sale | −30,902 | 13.17 | SEC filing |
| 2026-02-26 | Thomas Stephen Basil · Director | Common Stock | S — Open market or private sale | −16,313 | 7.01 | SEC filing |
| 2026-02-25 | Thomas Stephen Basil · Director | Common Stock | S — Open market or private sale | −33,687 | 7.00 | SEC filing |
| 2026-02-13 | Thomas Stephen Basil · Director | Common Stock | S — Open market or private sale | −10,000 | 5.81 | SEC filing |
| 2026-02-12 | Thomas Stephen Basil · Director | Common Stock | S — Open market or private sale | −90,000 | 5.23 | SEC filing |
| 2026-01-05 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +7,111 | 3.50 | SEC filing |
| 2025-12-12 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +101,462 | 2.86 | SEC filing |
| 2025-12-11 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | P — Open market or private purchase | +213,099 | 2.18 | SEC filing |
Showing 8 of 18 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-27 | Brennan Aoife · President and CEO | Restricted Stock Units | M — Exercise or conversion of derivative security | −68,750 | SEC filing |
| 2026-06-27 | Brennan Aoife · President and CEO | Common Stock | M — Exercise or conversion of derivative security | +68,750 | SEC filing |
| 2026-06-05 | Cumbo Alexander · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +40,000 | SEC filing |
| 2026-06-05 | Dunn Judith · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +40,000 | SEC filing |
| 2026-06-05 | Thomas Stephen Basil · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +40,000 | SEC filing |
| 2026-06-05 | WILLIAMS DOUGLAS E · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +40,000 | SEC filing |
| 2026-06-05 | RA Capital Healthcare Fund LP · Director, 10% owner | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +40,000 | SEC filing |
| 2026-06-05 | Levin Andrew David · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +40,000 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-12-11 | RA Capital Healthcare Fund LP · Director, 10% owner | Common Stock | D — Disposition to the issuer | −20,440,000 | SEC filing |
Showing 1 of 1 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.